

# INTEGRATED PROTEINS LIMITED

City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com)

CIN: L15400GJ1992PLC018426

Ref: IPL/BSE/Nov 2019

Date- 11<sup>th</sup> November, 2019

To,  
**Department of Corporate Service**  
BSE Limited  
PhirozJeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**Sub: Outcome of Board Meeting**

**Ref : Scrip Code - 519606**

Respected Sir / Madam,

With reference to captioned subject, and further to our letter dated 5<sup>th</sup> November, 2019, kindly be informed that the board in its meeting held today has interalia approved unaudited financial results for the quarter and half year ended on 30<sup>th</sup> September, 2019 along with the LRR for that period.

You are requested to take the same on your records.

Thanking you in anticipation.

**FOR, INTEGRATED PROTEINS LIMITED**

**Devanshi V. Shah (A50711)**  
**Company Secretary and Compliance Officer**



# INTEGRATED PROTEINS LIMITED

CIN: L15400GH1992PLC018426

Registered Office: 5TH Floor, City Point, Opp. Town Hall, Jamnagar, Gujarat-361001

## Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30 September, 2019

(Rs. In Lakh except per share data)

Particulars	Quarter Ended			Half Year Ended			Year Ended
	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019	
A	Date of start of reporting period	01/07/2019	01/04/2019	01/07/2018	01/04/2019	01/04/2018	01/04/2018
B	Date of end of reporting period	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Part I</b>							
I	<b>Revenue From Operations</b>						
	Net sales or Revenue from Operations	-	-	-	-	-	-
II	Other Income	4.14	4.00	4.30	8.14	8.62	17.22
III	<b>Total Revenue (I + II)</b>	<b>4.14</b>	<b>4.00</b>	<b>4.30</b>	<b>8.14</b>	<b>8.62</b>	<b>17.22</b>
IV	<b>Expenses</b>						
(a)	Cost of materials consumed	-	-	-	-	-	-
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	0.44	0.51	0.93	0.95	1.69	8.63
(e)	Finance Costs	-	-	0.04	-	0.05	0.06
(f)	Depreciation and amortisation expense	0.72	0.72	0.72	1.44	1.44	2.88
(g)	Other Expenses	0.37	3.53	0.41	3.92	4.60	5.34
	<b>Total expenses</b>	<b>1.53</b>	<b>4.76</b>	<b>2.11</b>	<b>6.31</b>	<b>7.78</b>	<b>16.91</b>
V	<b>Profit (loss) before Exceptional and</b>	<b>2.60</b>	<b>(0.77)</b>	<b>2.19</b>	<b>1.83</b>	<b>0.84</b>	<b>0.31</b>
VI	Exceptional items	-	-	-	-	-	-
VIII	<b>Profit (loss) before Tax (VII-VIII)</b>	<b>2.60</b>	<b>(0.77)</b>	<b>2.19</b>	<b>1.83</b>	<b>0.84</b>	<b>0.31</b>
X	<b>Tax Expense</b>	<b>0.68</b>	<b>(0.10)</b>	<b>0.21</b>	<b>0.58</b>	<b>0.21</b>	<b>(2.16)</b>
(a)	Current Tax	0.78	-	0.21	0.78	0.21	0.06
	(Less):- MAT Credit	-	-	-	-	-	0.06
	Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(b)	Deferred Tax (Asset)/Liabilities	(0.10)	(0.10)	-	(0.20)	-	(2.16)
XI	<b>Net Profit/Loss for the period from Continuing Operations (IX-X)</b>	<b>1.93</b>	<b>(0.67)</b>	<b>1.98</b>	<b>1.26</b>	<b>0.63</b>	<b>2.47</b>
XII	Profit (Loss) from Discontinuing Operations	-	-	-	-	-	-
XIII	Tax Expenses of Discontinuing Operations	-	-	-	-	-	-
XIV	<b>Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Profit (Loss) for the period (XI+XIV)</b>	<b>1.93</b>	<b>(0.67)</b>	<b>1.98</b>	<b>1.26</b>	<b>0.63</b>	<b>2.47</b>
XVI	<b>Other Comprehensive Income</b>						
	a. i). Amount of item that will not be reclassified to profit or loss	-	-	-	-	-	-
	ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b. i). Item that will be reclassified to profit or loss	-	-	-	-	-	-
	ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	<b>Total Comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Total Comprehensive income [Comprising Profit for the Period ( After tax) and Other comprehensive income ] (XV+XVII)</b>	<b>1.93</b>	<b>(0.67)</b>	<b>1.98</b>	<b>1.26</b>	<b>0.63</b>	<b>2.47</b>
XVIII	<b>Details of equity share capital</b>						
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	352.02	352.02	352.02	352.02	352.02	352.02
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX	<b>Reserves excluding revaluation reserve as per Balance Sheet</b>						
XX	<b>Earnings per share (Not Annualized for Quarter ended)</b>						
(a)	<b>Earnings per share Continuing Operation ( Not Annualised for Quarter ended )</b>						
	Basic earnings per share before extraordinary items	0.06	(0.02)	0.06	0.04	0.02	0.08
	Diluted earnings per share before extraordinary items	0.06	(0.02)	0.06	0.04	0.02	0.08
(b)	<b>Earnings per share Discontinuing Operation ( Not Annualised for Quarter ended )</b>						
	Basic earnings per share after extraordinary items	-	-	-	-	-	-
	Diluted earnings per share after extraordinary items	-	-	-	-	-	-
(c)	<b>Earnings per share ( Not Annualised for Quarter ended )</b>						
	Basic earnings per share before extraordinary items	0.06	(0.02)	0.06	0.04	0.02	0.08
	Diluted earnings per share before extraordinary items	0.06	(0.02)	0.06	0.04	0.02	0.08

**Notes:-****Notes to Unaudited financials results for the quarter and half year ended September 30, 2019:**

- |   |   |
|---|---|
| 1 | The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on November 11, 2019. These results have been subject to limited review by the statutory auditors. |
| 2 | The Company has single reportable business segment. Hence, no separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".                                    |
| 3 | The Financial Results have been reviewed by the Statutory Auditors as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.  |
| 4 | The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.  |

For, Integrated Protiens Limited

Piyush C Vora

Director

Date :- 11/11/2019

Place :- Jamnagar

Din: 00296074

# INTEGRATED PROTEINS LIMITED

CIN: L15400GJ1992PLC018426

Registered Office: 5TH Floor , City Point , Opp. Town Hall, Jamnagar,Gujarat-361001

## Unaudited Standalone Statement of Assets and Liabilities

(Rs. In Lakh)

	Particulars	Year Ended	
		30/09/2019	31/03/2019
A	Date of start of reporting period	01/04/2019	01/04/2018
B	Date of end of reporting period	30/09/2019	31/03/2019
C	Whether results are audited or unaudited	Unaudited	Audited
	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
a)	Property, Plant and Equipment	50.83	52.28
b)	Capital work-in-progress	-	-
c)	Investment Property	-	-
d)	Goodwill	-	-
e)	Other Intangible assets	-	-
f)	Intangible assets under development		
g)	Biological Assets other than bearer plants		
h)	Investments accounted for using equity method		
i)	Financial Assets		
(i)	Investments	0.03	0.03
(ii)	Trade receivables	2.63	2.63
(iii)	Loans	134.00	126.50
(iv)	Security Deposits		
i)	Deferred tax assets (net)		
j)	Other non-current assets	37.74	37.74
<b>2</b>	<b>Current assets</b>		
a)	Inventories	-	-
b)	Financial Assets		
(i)	Investments		
(ii)	Trade receivables		
(iii)	Cash and cash equivalents	4.17	3.81
(iv)	Bank balances other than Cash and cash equivalents	19.40	29.69
(v)	Loans	-	-
(vi)	Others		
c)	Current Tax Assets (Net)	0.98	1.66
d)	Other current assets	1.52	1.00
<b>3</b>	<b>Non-current assets classified as held for sale</b>		
<b>4</b>	<b>deferred tax assets</b>		
	<b>Total Assets</b>	<b>251.30</b>	<b>255.33</b>
	<b>EQUITY &amp; LIABILITIES:</b>		
	<b>Equity</b>		
a)	Equity Share capital	352.02	352.02
b)	Other Equity	(108.19)	(109.45)
	<b>Liabilities</b>		
<b>1)</b>	<b>Non-Current Liabilities</b>		
a)	Financial Liabilities	-	-
(i)	Borrowings	-	-
(ii)	Trade payables		
(iii)	Other financial liabilities (other than those specified in item (b), to be specified)		
b)	Provisions		
c)	Deferred tax liabilities (Net)	2.84	3.04
d)	Deferred government grants (non current)	-	-
e)	Other non-current liabilities		

<b>2)</b>	<b>Current liabilities</b>		
a)	Financial Liabilities		
(i)	Borrowings	-	-
(ii)	Trade payables	4.28	9.31
(iii)	Other financial liabilities		
b)	Provisions	-	-
c)	Income/Current Tax Liabilities (Net)		
d)	Other current liabilities	0.35	0.42
<b>Total Liabilities</b>		<b>251.30</b>	<b>255.33</b>

For, Integrated Protiens Limited



Piyush C Vora  
Director

Din: 00296074

Date :- 11/11/2019

Place :- Jamnagar

# INTEGRATED PROTEINS LIMITED

CIN: L15400GJ1992PLC018426


Registered Office: 5TH Floor, City Point, Opp. Town Hall, Jamnagar, Gujarat-361001

Cash Flow Statement for the half year ended 30th September, 2019

(Rs. In Lakhs)

	Particulars	As on 30th September, 2019	As on 30th September, 2018
		Rs.	Rs.
<b>A.</b>	<b>Cash flow from operating activities</b>		
	Profit before Tax	1.83	0.83
	<b>Adjustments for:</b>		
	Depreciation and amortisation	1.44	1.44
	Finance costs	-	0.05
	<b>Operating profit / (loss) before working capital changes</b>	<b>3.27</b>	<b>2.32</b>
	<b>Movements in Working Capital</b>		
	(Increase) / Decrease Other Current Assets	(0.52)	(0.79)
	Increase / (Decrease) Trade payables	(5.03)	0.49
	Increase / (Decrease) Other current liabilities	(0.11)	(0.37)
	<b>Net Cash Generated/(Used in) Operations</b>	<b>(5.66)</b>	<b>(0.67)</b>
	Direct Taxes Paid including for past years	0.04	0.04
	<b>Net cash flow from / (used in) operating activities (A)</b>	<b>(2.43)</b>	<b>1.61</b>
<b>B.</b>	<b>Cash flow from Investing activities</b>		
	<b>Net cash flow from / (used in) investing activities (B)</b>	-	-
<b>C.</b>	<b>Cash flow from financing activities</b>		
	Finance cost	-	(0.05)
	(Increase) / Decrease Long-term loans and advances	(7.50)	(7.50)
	<b>Net cash flow from / (used in) financing activities (C)</b>	<b>(7.50)</b>	<b>(7.55)</b>
	<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>	<b>(9.93)</b>	<b>(5.94)</b>
	Cash and cash equivalents at the beginning of the year	33.50	40.74
	<b>Cash and cash equivalents at the end of the year *</b>	<b>23.57</b>	<b>34.80</b>
	<b>* Comprises:</b>		
	(a) Cash on hand	4.17	3.48
	(b) Balances with banks		
	(i) In current accounts	19.40	31.31
	(ii) In deposit accounts	-	-
		<b>23.57</b>	<b>34.80</b>

For, Integrated Proteins Limited



Piyush C Vora

Director

Din: 00296074

Date :- 11/11/2019

Place :- Jamnagar



**Independent Auditor's Review Report On The Unaudited Standalone Financial Results for  
Quarterly and Six Months Ended 30th September 2019**

**Review Report to  
The Board of Directors of  
INTEGRATED PROTEINS LIMITED,**

1. We have reviewed the accompanying statement of standalone unaudited financial results of Integrated Proteins Limited ('the Company') for the quarter ended September 30, 2019 and for the six months ended September 30, 2019 ('the Statement').
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement of principles laid done in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our Responsibility is to issue a report on the statement based on our review.
3. We conducted our Review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standards requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we done express an audit opinion





**Sarvesh A. Gohil**

B.Com., F.C.A.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



**For, Doshi Maru & Associates  
Chartered Accountants  
FRN: 0112187W**



**Sarvesh A. Gohil  
Partner**

**Membership No. 135782**

**UDIN: 19135782AAAAMZ4646**

**Date: 11/11/2019**

**Place: Jamnagar**